{"id":"licensed-quadrivalent-hpv-vaccine-gardasil","safety":{"commonSideEffects":[{"rate":"~80%","effect":"Injection site pain"},{"rate":"~25%","effect":"Injection site swelling"},{"rate":"~25%","effect":"Injection site erythema"},{"rate":"~10-15%","effect":"Headache"},{"rate":"~10%","effect":"Fever"},{"rate":"~5-10%","effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL2108573","moleculeType":"Vaccine component"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine contains virus-like particles (VLPs) derived from the major capsid protein of HPV types 6, 11, 16, and 18. When administered, these VLPs trigger a humoral immune response that generates neutralizing antibodies against these HPV types, preventing infection and subsequent development of HPV-related diseases. This prophylactic approach prevents cervical cancer, genital warts, and other HPV-associated malignancies before infection occurs.","oneSentence":"Gardasil is a quadrivalent vaccine that stimulates the immune system to produce antibodies against four types of human papillomavirus (HPV types 6, 11, 16, and 18).","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:18:49.277Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of cervical cancer caused by HPV types 16 and 18"},{"name":"Prevention of genital warts caused by HPV types 6 and 11"},{"name":"Prevention of anal cancer and other HPV-related cancers"}]},"trialDetails":[{"nctId":"NCT05329961","phase":"EARLY_PHASE1","title":"Immunogenicity of the 9vHPV Vaccination 2-dose Regimen Among Children 4 to 8 Years Old","status":"ACTIVE_NOT_RECRUITING","sponsor":"Boston Medical Center","startDate":"2022-09-26","conditions":"Human Papilloma Virus","enrollment":155},{"nctId":"NCT04590521","phase":"PHASE4","title":"HPV Vaccine Immunity in High-risk Women","status":"COMPLETED","sponsor":"Murdoch Childrens Research Institute","startDate":"2022-09-14","conditions":"HPV Infection","enrollment":63},{"nctId":"NCT02968420","phase":"PHASE4","title":"Long Term Immune Memory Responses to HPV Vaccination Following 2 vs 3 Doses of Quad-HPV Vaccine","status":"COMPLETED","sponsor":"University of British Columbia","startDate":"2017-09-11","conditions":"Human Papillomavirus","enrollment":18},{"nctId":"NCT00964210","phase":"PHASE3","title":"Protecting Young Special Risk Females From Cervical Cancer Through Human Papilloma Virus (HPV) Vaccination","status":"COMPLETED","sponsor":"Murdoch Childrens Research Institute","startDate":"2008-03","conditions":"Cervical Cancer","enrollment":240}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Licensed quadrivalent HPV vaccine, Gardasil","genericName":"Licensed quadrivalent HPV vaccine, Gardasil","companyName":"Murdoch Childrens Research Institute","companyId":"murdoch-childrens-research-institute","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Gardasil is a quadrivalent vaccine that stimulates the immune system to produce antibodies against four types of human papillomavirus (HPV types 6, 11, 16, and 18). Used for Prevention of cervical cancer caused by HPV types 16 and 18, Prevention of genital warts caused by HPV types 6 and 11, Prevention of anal cancer and other HPV-related cancers.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}